Results 41 to 50 of about 7,202 (139)
Molecular Genetics and Metabolism ReportsVascular involvement in the genetic disorder mucopolysaccharidosis type I (MPS I) has features of atherosclerotic disease near branch points of arterial vasculature, such as intimal thickening with disruption of the internal elastic lamina, and ...
Sarah C. Hurt +5 more
doaj +1 more source
Indian Journal of Dermatology, 2011 The primary cutaneous T-cell lymphomas (CTCL) represent a clonal T-lymphocyte proliferation infiltrating the skin. CD30+ T-cell lymphomas present clinically as nodules with a diameter between 1 and 15 cm, mostly in elderly patients.
Georgi Tchernev +3 more
doaj
Expression of CD30 Ligand (CD153) on Murine Activated T Cells
Biochemical and Biophysical Research Communications, 1999 CD30, a member of the TNF receptor family, has been implicated in the activation of T cells and B cells. In the present study, we characterized the expression and function of murine CD30 ligand (mCD153) by utilizing mCD153 transfectants and a novel mAb against mCD153 (RM153), which can inhibit the binding of murine CD30 to mCD153.
O, Shimozato +3 more
openaire +3 more sources
Immunotherapy‐Related Cutaneous Toxicities in Melanoma: A Dermoscopic Perspective
JEADV Clinical Practice, Volume 5, Issue 2, Page 402-414, June 2026.Dermoscopy serves as a valuable tool in the everyday dermatological and oncological practice for melanoma patients, allowing for the prompt identification of immune‐related cutaneous toxicities and guiding clinicians toward appropriate therapeutic decisions.
Grażyna Kamińska‐Winciorek +3 more
wiley +1 more source
Diagnosing Systemic Mastocytosis: State of the Art
International Journal of Laboratory Hematology, Volume 48, Issue 3, Page 551-560, June 2026.ABSTRACT With the advent of effective multikinase and selective tyrosine kinase inhibitors in systemic mastocytosis, diagnosing this rare disease has been critical to improving patient morbidity and mortality. This state‐of‐the‐art review interprets the international diagnostic criteria, including differences between the WHO 5th edition classification ...
Anton Rets, Tracy I. George
wiley +1 more source
The NF‐κB Signalling Pathway: Mechanisms, Consequences and Therapeutic Targets
Journal of Cellular and Molecular Medicine, Volume 30, Issue 11, June 2026.ABSTRACT Nuclear Factor‐kappa B (NF‐κB) is a master transcriptional regulator orchestrating critical cellular processes, predominantly immunity and inflammation. However, its aberrant constitutive activation has emerged as a unifying pathogenetic hallmark across diverse malignancies, autoimmune disorders, and chronic inflammatory diseases.
Bherouz Pourdad, Arash Pourdad
wiley +1 more source
Identifying potential drug targets for myocardial infarction through Mendelian randomization.
PLoS ONEBackgroundThis study explored the associations between plasma and cerebrospinal fluid (CSF) proteins and myocardial infarction (MI) risk. Identifying specific proteins as biomarkers for MI could enhance our understanding of disease mechanisms and inform ...
Xiangyou Yu, Shasha Liu
doaj +1 more source
Molecular Oncology, Volume 20, Issue 5, Page 1220-1236, May 2026.Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang +3 more
wiley +1 more source
Choosing between Nivo‐AVD and BrECADD: Hodgkin lymphoma's new era
British Journal of Haematology, Volume 208, Issue 6, Page 2239-2242, June 2026.
Edward R. Scheffer Cliff +2 more
wiley +1 more source
Plenary Abstracts Session & Oral Presentations
HemaSphere, Volume 10, Issue S1, June 2026.
wiley +1 more source